Vontobel Holding Ltd. Takes $297,000 Position in Omnicell, Inc. (NASDAQ:OMCL)

Vontobel Holding Ltd. bought a new stake in Omnicell, Inc. (NASDAQ:OMCL) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 6,681 shares of the company’s stock, valued at approximately $297,000.

A number of other institutional investors and hedge funds have also made changes to their positions in OMCL. Creative Planning raised its holdings in shares of Omnicell by 23.1% in the third quarter. Creative Planning now owns 11,667 shares of the company’s stock valued at $509,000 after buying an additional 2,188 shares during the last quarter. Roubaix Capital LLC purchased a new stake in shares of Omnicell in the third quarter valued at about $1,851,000. 1620 Investment Advisors Inc. increased its stake in shares of Omnicell by 230.1% during the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after acquiring an additional 1,542 shares during the period. Rice Hall James & Associates LLC acquired a new position in shares of Omnicell during the third quarter worth about $2,723,000. Finally, QRG Capital Management Inc. acquired a new position in shares of Omnicell during the third quarter worth about $231,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Stock Up 0.2 %

Shares of NASDAQ OMCL opened at $39.72 on Friday. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $55.74. The company has a market capitalization of $1.84 billion, a PE ratio of 147.12, a price-to-earnings-growth ratio of 7.62 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. The firm’s 50-day moving average is $43.09 and its two-hundred day moving average is $43.85.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. Equities analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their price target on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Barclays boosted their price target on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Benchmark reiterated a “buy” rating and set a $62.00 price target on shares of Omnicell in a research note on Tuesday, February 4th. Finally, Wells Fargo & Company dropped their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $52.33.

Insider Buying and Selling at Omnicell

In related news, Director Mark W. Parrish sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the transaction, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 2.64% of the company’s stock.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.